Dr. David A. Braun delved into the molecular factors which drive exceptional responses to immunotherapy in metastatic clear cell renal cell carcinoma.

A panelist discusses how caregivers can support patients with polycythemia vera (PV) by helping track symptoms, managing medical appointments and recognizing warning signs that require physician ...

Among patients with advanced PIK3CA-mutated, HR-positive/HER2-negative breast cancer, Itovebi-based treatment generated positive overall survival results.

The first patient has been dosed in a phase 1 dose-finding clinical trial evaluating iadademstat with Vidaza in patients with ...

The combination of Opdivo and Yervoy is supported by updated results as a standard of care for MSI-H or dMMR metastatic ...

For a person who loved to hike; do aerobic exercises with Billy Blanks, Gilead, Denise Austin and Jane Fonda every day (I ...

Dr. Anna Arthur discusses the NOURISH trial, which aims to address food insecurity and malnutrition in patients with blood ...

The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic ...

Brukinsa had a lower risk of disease progression or death versus Imbruvica, as well as a more favorable safety profile, in R/R CLL and SLL.

After a long and difficult journey, I finally published the book I set out to write as my legacy, overcoming cancer and the ...

In patients with RCC, exceptional response to immunotherapy may be related to clonal neoantigen-driven cytotoxic T-cell ...

Dr. Ritu Salani shared her advice for patients undergoing advanced treatment options for their cervical cancer who are ...